Placebo-controlled study in neuromyelitis optica—Ethical and design considerations

Placebo studies should not be undertaken in NMO – No

(2015) Benjamin M Greenberg   Multiple Sclerosis Journal

Placebo studies should not be undertaken in NMO – Yes

(2015) Jacqueline Palace   Multiple Sclerosis Journal

Placebo Studies should not be Undertaken in Neuromyelitis Optica: Commentary

(2015) Brian G Weinshenker   Multiple Sclerosis Journal

Demographic and clinical features of neuromyelitis optica: A review

(2015) L Pandit et al.   Multiple Sclerosis Journal

Challenges and opportunities in designing clinical trials for neuromyelitis optica

(2015) B. G. Weinshenker et al.   NEUROLOGY

Placebo studies should not be undertaken in NMO – No

(2015) Benjamin M Greenberg   Multiple Sclerosis Journal

Placebo studies should not be undertaken in NMO – Yes

(2015) Jacqueline Palace   Multiple Sclerosis Journal

Placebo Studies should not be Undertaken in Neuromyelitis Optica: Commentary

(2015) Brian G Weinshenker   Multiple Sclerosis Journal

Demographic and clinical features of neuromyelitis optica: A review

(2015) L Pandit et al.   Multiple Sclerosis Journal

Placebo controlled trials in neuromyelitis optica are needed and ethical

(2015) Bruce A.C. Cree   Multiple Sclerosis and Related Disorders

Treatment of neuromyelitis optica: state-of-the-art and emerging therapies

(2014) Marios C. Papadopoulos et al.   Nature Reviews Neurology

Mycophenolate Mofetil to Treat Neuromyelitis Optica

(2014) Bruce Cree   JAMA Neurology

Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS)

(2013) Corinna Trebst et al.   JOURNAL OF NEUROLOGY

Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study

(2013) Sean J Pittock et al.   LANCET NEUROLOGY

Statistical cures and other fallacies

(2012) Gary R Cutter   Multiple Sclerosis Journal

Randomized controlled trial of atorvastatin in clinically isolated syndrome: The STAyCIS study

(2012) E. Waubant et al.   NEUROLOGY

Treatment of neuromyelitis optica: Review and recommendations

(2012) Dorlan J. Kimbrough et al.   Multiple Sclerosis and Related Disorders

Repeated Treatment With Rituximab Based on the Assessment of Peripheral Circulating Memory B Cells in Patients With Relapsing Neuromyelitis Optica Over 2 Years

(2011) Su-Hyun Kim   ARCHIVES OF NEUROLOGY

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

(2011) Ludwig Kappos et al.   LANCET

Impact of rituximab on relapse rate and disability in neuromyelitis optica

(2011) Gurdesh S Bedi et al.   Multiple Sclerosis Journal

Azathioprine: Tolerability, efficacy, and predictors of benefit in neuromyelitis optica

(2011) C. Costanzi et al.   NEUROLOGY

EFNS guidelines on diagnosis and management of neuromyelitis optica

(2010) J. Sellner et al.   EUROPEAN JOURNAL OF NEUROLOGY

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

(2009) G Comi et al.   LANCET

Levels of evidence: Taking Neurology(R) to the next level

(2009) R. A. Gross et al.   NEUROLOGY

Treatment of Neuromyelitis Optica With Rituximab

(2008)   ARCHIVES OF NEUROLOGY

An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis

(2008) D. B. Sanders et al.   NEUROLOGY

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE